Instead, I favor an options strategy that pays me to get long at a discount. Specifically, I like selling the June $360 puts at $10 (or better) rather than purchasing the stock at the moment for several reasons.
The market is stretched:
First, equity valuations generally are quite stretched. Forward looking S&P 500 price-to-earnings multiples may not set off alarm bells at roughly 21x, but measures which seek to view valuations through business cycles, such as the Schiller CAPE (cyclically adjusted pe) ratio are nearing historical highs. JP Morgan’s long-term valuation studies show that when multiples are elevated, subsequent 5–10‑year returns tend to be lower than average. If that’s true, investors may want to consider strategies that generate “standstill returns”.
Selling options premium — specifically, cash‑secured puts — offers a way to express constructive views on quality companies while being paid to wait for attractive entry points.
The company has turned the corner…
The reason? UNH went through a period of strategic missteps, primarily linked to cost pressures and execution issues within its Optum unit. However, the reappointment of its previous CEO has begun to restore market confidence. Early signs suggest a renewed operational discipline and refocus on core capabilities — integrating healthcare delivery, insurance, and analytics — creating potential for margin recovery. AI could also help speed healthcare services, improve outcomes and lower costs; important improvements for a managed care provider.
Insurers may benefit from AI
THE TRADE:
- Sell the June 360-strike put for $10
- Max Gain: $10
- Breakeven: $350
- Max Loss $350
- Intermediate level trade that will tie up cash/margin
Selling a cash‑secured put allows investors to monetize options premia while setting a disciplined entry point approximately 5% below current market prices. If the option expires worthless, the seller keeps the premium as income. If assigned, the investor effectively buys UNH shares at a discount, lowering their cost basis versus today’s level.
In both scenarios, the trade reflects a “getting paid to wait” philosophy: earning yield on sidelined cash while positioning for long-term participation in one of the strongest franchises in American healthcare. In this case the nearly 2.8% yield to expiration works out to approximately 22% annualized.
In the event one is assigned the stock, the effective purchase price will be $350/share (the $360 put strike less the premium collected) – a level that corresponds to the most recent price jump. If one is assigned, one could further lower one’s basis by consistently selling covered calls against the resulting long equity position.
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.